CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	5,946	6,026	5,791	5,996	6,216
Revenue Growth (YoY)	2.54%	4.05%	-3.41%	-3.54%	-
Cost of Revenue	3,630	3,522	3,657	3,603	3,233
Gross Profit	2,316	2,504	2,135	2,392	2,983
Selling, General & Admin	622.51	634.26	553.03	766.18	799.66
Other Operating Expenses	-55.14	-53.95	-17.35	-40.06	-27.07
Operating Expenses	567.37	580.31	535.68	726.12	772.59
Operating Income	1,748	1,924	1,599	1,666	2,211
Interest Expense	-183.36	-202.03	-220.91	-143.76	-6.46
Interest & Investment Income	12.34	28.55	26.82	29.62	2.04
Currency Exchange Gain (Loss)	-3.4	-2.14	-2.07	-3.93	-1.55
EBT Excluding Unusual Items	1,591	1,748	1,403	1,548	2,205
Asset Writedown	-1.01	-3.08	-1.73	-20.22	-2.17
Pretax Income	1,590	1,745	1,401	1,528	2,202
Income Tax Expense	456.81	506.36	400.33	427.25	674
Earnings From Continuing Operations	1,133	1,239	1,001	1,101	1,528
Minority Interest in Earnings	-11.97	-13.68	-9.55	-14.22	-10.5
Net Income	1,121	1,225	991.13	1,087	1,518
Net Income to Common	1,121	1,225	991.13	1,087	1,518
Net Income Growth	-1.64%	23.62%	-8.78%	-28.42%	-
Shares Outstanding (Basic)	26,791	30,058	30,058	30,058	-
Shares Outstanding (Diluted)	26,791	30,058	30,058	30,058	-
EPS (Basic)	0.04	0.04	0.03	0.04	-
EPS (Diluted)	0.04	0.04	0.03	0.04	-
EPS Growth	10.35%	23.63%	-8.78%	-	-
Free Cash Flow	1,672	1,753	1,577	1,802	-
Free Cash Flow Per Share	0.06	0.06	0.05	0.06	-
Dividend Per Share	-	0.043	0.043	-	-
Dividend Growth	-	0.51%	-	-	-
Gross Margin	38.95%	41.56%	36.86%	39.90%	47.99%
Operating Margin	29.40%	31.93%	27.61%	27.79%	35.56%
Profit Margin	18.85%	20.33%	17.11%	18.12%	24.42%
Free Cash Flow Margin	28.12%	29.09%	27.23%	30.05%	-
EBITDA	2,287	2,461	2,156	2,118	2,714
EBITDA Margin	38.46%	40.83%	37.23%	35.32%	43.66%
D&A For EBITDA	538.57	536.71	557.14	451.58	503.28
EBIT	1,748	1,924	1,599	1,666	2,211
EBIT Margin	29.40%	31.93%	27.61%	27.79%	35.56%
Effective Tax Rate	28.74%	29.01%	28.57%	27.96%	30.60%

Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.